Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB10 | P40306 | 2/20 | 0.51 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.48 |
| ▸ | CTRL | P40313 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.48 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.48 |
| ▸ | CYP3A43 | Q9HB55 | 2/20 | 0.48 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.48 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.48 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.48 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.48 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.48 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.48 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569025 | 1.00 | PSMB10 (0.51) | PSMB10PSMB2SMN1; SMN2TMPRSS11DCTRL | |
| SCHEMBL16463485 | 0.86 | CYP3A4 (0.47) | PSMB10PSMB2TMPRSS11DCTRLPSMB5 | |
| SCHEMBL16463487 | 0.86 | CYP3A4 (0.47) | PSMB10PSMB2TMPRSS11DCTRLPSMB5 | |
| SCHEMBL16910569 | 0.85 | PSMB10 (0.48) | PSMB10PSMB2TMPRSS11DCTRLPSMB5 | |
| SCHEMBL16970533 | 0.85 | PSMB10 (0.48) | PSMB10PSMB2TMPRSS11DCTRLPSMB5 | |
| SCHEMBL12883690 | 0.84 | SIGMAR1 (0.51) | ALDH1A1NTSR1MEN1LMNAKMT2A | |
| SCHEMBL16119345 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL16227661 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL16910580 | 0.83 | PSMB10 (0.50) | PSMB10PSMB2TMPRSS11DCTRLPSMB5 | |
| SCHEMBL20185886 | 0.82 | CYP3A4 (0.51) | PSMB10PSMB2SMN1; SMN2TMPRSS11DCTRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | claimed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | claimed |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-07-23 | — | — | US | claimed |
| EP-2885314-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | Fluorinov Pharma Inc. (CA) | 2015-06-24 | — | — | EP | claimed |
| WO-2014026282-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | SLASSI ABDELMALIK (CA) | 2014-02-20 | — | — | WO | claimed |
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-07-23 | — | — | US | disclosed |
| EP-2885314-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | Fluorinov Pharma Inc. (CA) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014026282-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | SLASSI ABDELMALIK (CA) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | PSMB10 14/4885PSMB2 6/4885SMN1; SMN2 2029/4885 |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | PSMB10 14/4885PSMB2 6/4885SMN1; SMN2 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.